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Summary The production of the cytokines IFN-gamma, IL-1-alpha, IL-2 and TNF-alpha was investigated in
mitogen-stimulated, whole blood cell culturs from 239 untreated patients with primary gynaecological car-
cinomas (breast, cervix, ovary, endometrium), and 191 healthy female controls.
The cytokines were measured in the 4-day post-inductional supernatants by a sensitive enzymoim-
munological assay. In the blood cell cultures of all four groups of cancer patients, significantly lower values of
IFN-gamma (P < 0.001), IL-2 (P < 0.01) and IL-1 alpha (P < 0.01) were found as compared to the controls,
although lymphocyte and monocyte counts were almost identical.
Grouping the tumour patients into different clinical stages we could show in the four groups of carcinomas
a gradual depression of the cytokine production according to growing tumour burden.
The host's response to malignant tumours is usually con-
sidered to be primarily a function of the cellular immune
system and various tests have been established to measure
the integrity of this system in cancer patients, such as
hypersensitivity skin tests (Bolton et al., 1975; Evans et al.,
1977), or determination of mitogen-induced lymphocyte pro-
liferation in vitro (Dean et al., 1977; Zembala et al., 1977;
Fritze & Dystant, 1984).
As the cell-mediated immune response is controlled by a
series of soluble cytokines, in recent years the measurement
of these substances has also been used to determine the
cellular immunological potency of tumour patients (Rey et
al., 1983; Santos et al., 1985; Elsasser-Beile et al., 1991a).
The current report focuses on measurements of several
cytokines, produced by peripheral lymphocytes and
monocytes upon initial triggering with a mitogenic stimula-
tion and their evaluation as parameters for the actual
immunity potential of tumour patients and controls.
The aim was to apply an easy-to-handle and reproducible
whole blood cell culture system to a large patient group,
investigating whether cellular immunity is depressed in these
tumour patients and ifthere is a correlation between cytokine
levels and growing tumour mass.
Materials and methods
Patients
A total of 239 patients aged between 23 and 89 years (mean
54 years) with histologically verified gynaecological malig-
nancies, were screened in this study and grouped as follows:
The first group was composed of 87 patients with breast
cancer (34 of them with only a small primary tumour-TI/
T2, No, Mo-and 53 with lymph node and/or organ
metastases-T3/T4, N + and/or M + ), 63 patients with cer-
vical carcinomas (23 FIGO stage I, 23 stage II, 17 stage
III/IV), 47 patients with ovarian carcinomas (13 stage I/II, 34
stage III/IV), and 43 patients with endometrial carcinomas
(23 stage I/TI, 20 stage III/IV). All patients were untreated
and blood was taken preoperatively.
Controls (n = 191) were normal healthy female blood
donors, aged between 20 and 72 years (mean 42 years).
Bloodsamples
Ten ml of heparinised blood was taken from each patient
and control person between 9 and 11 a.m. The samples, kept
at room temperature, were used within 2 h. A 0.5 ml aliquot
was removed for total and differential leukocyte counts.
Whole blood cell culture (WBCC)
Cultures were performed as previously described with a
system for which optimal conditions and kinetics of cytokine
production were established (Elsasser-Beile et al., 1991b).
In brief, heparinised venous blood was diluted 1/10 with
RPMI 1640 (Seromed, Berlin FRG), which was supple-
mented with 50 Uml-' Penicillin (Seromed) and 50 Sgml-'
Streptomycin (Seromed) and distributed in 0.5 ml aliquots in
12 mm polystyrol tubes. For stimulation, 10igml-' phyto-
haemagglutinin (PHA Wellcome, Burgwedel, FRG) and
0.5-5 g.g ml-' Pokeweed mitogen (PWM, Sigma, Deisen-
hofen, FRG) were added.
Incubation of the cell cultures was performed at 37°C in a
humidified atmosphere of 5% CO2. After 4 days of culture
without changes of medium 320ftl of supernatant was
removed from each tube to be assayed for cytokine levels.
Determination ofcytokines
Enzyme-linked immunoassays (ELISA) were applied for
qualitative and quantitative determinations of cytokines.
These tests are based on the sandwich principle and are
performed in one step. Since a correlation was found between
assay performance of the naturally occurring cytokines and
their recombinant counterparts, the latter were used as stan-
dards.
Interferon-gamma-ELISA
IFN-gamma levels in the supernatants were determined as
previously described (Gallati et al., 1987). In brief, the IFN-
gamma containing supematants and the samples for the
IFN-gamma standard curve were distributed with a horse
radish peroxidase(pod)-labelled monoclonal antibody to
IFN-gamma (Clone 69) in microtiter plates previously coated
with the same clone-69-monoclonal antibody against IFN-
gamma. After an incubation period of 24 h, unbound
material was removed by a washing step and the amount of
bound peroxidase was determined by a short incubation with
tetramethylbenzidin. On stopping the reaction with sulphuric
acid the colour changed to yellow and its intensity was
determined at 450 nm by a computerised multichannel
photometer (Flow, Meckenheim, FRG). The amount of
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human IFN-gamma was calculated from the standard curve
prepared with recombinant IFN-gamma.
This ELISA has an assay range of 50-1,000 pg ml1- IFN-
gamma.
Interleukin-l-alpha ELISA
This test works on the same principle as the IFN-gamma
test. Microtitre plates were coated with a polyclonal goat
anti-human IL-l-alpha antibody. For the detection ofprotein
bound IL-1 alpha the pod-linked Fab-fragment of a poly-
clonal goat-anti-human-IL-i-alpha antibody was used. The
standard was recombinant IL-l-alpha.
(Assay range: 10-100pgml-' IL-1 alpha).
TNF-alpha-ELISA
In this test, the first immobilised antibody was a monoclonal
mouse anti-human-TNF-alpha-antibody and the second a
pod-coupled polyclonal rabbit anti-human-TNF-alpha-
antibody. Recombinant TNF-alpha was used as standard.
The assay range is 20-500pg ml' TNF-alpha.
Interleukin-2-ELISA
For this test, microtitre plates were coated with two mono-
clonal mouse anti-human IL-2 antibodies, and a third pod-
linked mab was used for detection of bound IL-2. (assay
range: 50-1,000 pg ml-' IL-2).
Statistical analysis
The results in the tumour- and control group were statisti-
cally evaluated using the Programs BMDP2VR (Statistical
Software Dptm, of Biomathematics, University of California,
L.A.) and SASRGLM (SAS Institute Inc. Cary, NC, USA).
Due to the skewed distribution, all values were logarith-
mically transformed in preparation for variance analysis.
Results
Cytokine values in the whole blood cell cultures (WBCC) of
healthy women
Upon stimulation with the mitogens phytohaemagglutinin
and pokeweed mitogen, a normal range of cytokine produc-
Table I Median values
tion the cultures of the 191 healthy female controls could be
established and the observed wide range of values may cor-
respond to a broad physiological variation of cellular
immunity within the normal population. The values followed
a skewed distribution, therefore data were presented as 'box
plots' and not as mean standard deviation. There was a
dependence of the values on the age of the persons in as far
as the levels were somewhat lower in elderly individuals than
in younger subjects (regression coefficient 0.01) and this was
considered in the statistical calculations.
IFN-gamma values ranged between 10 and 375 ngml-l
with median values of 77 ng ml upon stimulation with 10 iLg
ml1' PHA and 108 ng IFN-gamma ml-' ml upon stimulation
with 5ygml'l PWM.
IL-2 levels were between 0 and 14,955pgml-' (median
1,055 pgml-l for PHA-stimulation and 1,525 pgmll for
PWM-stimulation).
The levels of the monokines were between 10 and 1,100 pg
ml1' for IL-1-alpha and between 0 and 4,093pgml-' for
TNF-alpha (Table I).
Cytokine values in the WBCC ofpatients with breast cancer
In the whole blood cell cultures of the 87 patients with breast
cancer significantly lower values of IFN-gamma (P .0.001),
IL-1-alpha (P. 0.01) and IL-2 (P. 0.001) were measured
compared to the controls (Table 1).
Considering different tumour stages we found that a
decreased IFN-gamma production correlated with tumour
burden: cells of the 53 patients with lymph node and/or
distant organ metastases (N + M + ) produced values lower
than those of 34 patients with only a small localised tumour
(T1/T2, NO, MO). The differences were significant (P .0.05)
and the distribution of the values is shown in Figure 1.
There also were lower IL-l-alpha and IL-2 values in the
cultures of the patients with metastasising tumours, however,
the differences between the groups were not statistically
significant.
Cytokine values in the WBCC ofpatients with cervical
carcinoma
If patients with cervical carcinomas in all clinical stages were
taken together, only small differences in their blood cell
cytokine production could be shown compared to the con-
trols.
and ranges of cytokine levels in whole blood cell cultures of patients with gynaecological tumours and
controls (not considering different stages)
Cytokine Controls Cervical Ca Breast Ca Endometrial Ca Ovarian Ca
IFN-gamma [ngml']
PHA median 77 46 46 34 25
range 10-250 5-239 2-251 5-137 1-169
PWM median 108 81 65 37 35
range 22-375 5-339 5-266 0-186 1-165
Difference to controls P<0.01 P 0.001 P. 0.001 P<0.001
IL-2 [pgml']
PHA median 1,055 1,156 654 568 535
range 0-14,955 0-10,345 0-11,302 0-2,633 0-12,933
PWM median 1,525 1,263 963 568 630
range 108-10,293 0-10,698 0-9,048 0-3,531 40-5,595
Difference to controls n.s. P<0.001 P<0.01 P<0.01
IL-1-alpha [pgml-']
PHA median 115 100 96 97 85
range 5-630 0-360 0-450 0-253 0-200
PWM median 275 220 230 202 189
range 40-1,100 50-704 13-792 8-570 17-383
Difference to controls P<0.05 P<0.01 P 0.01 P<0.01
TNF [pgml']
PHA median 563 532 535 260 308
range 0-4,093 0-4,855 0-3,980 0-3,355 0-3,455
PWM median 418 459 375 226 270
range 0-2,625 0-2,648 0-2,090 0-1,941 0-1,813
Difference to controls n.s. n.s. n.s. n.s.34 U. ELSASSER-BEILE et al.
250[
- 25
E
'm 20 c
E
E 1E
CD
z
IY
200k
Contents Breast cancer
a b
Max
E
0)
E
E
cU
0
z
LL
Q3
Med
Q1
Min
Figure 1 IFN-gamma levels in mitogen-stimulated, whole blood
cell cultures of patients with breast cancer. Mitogen: PWM
5 lgml-. a, Tl/T2, NO, MO, b, T>2, N+ and/or M+,
Min= minimal value, Max = maximal value, Med = median,
Ql = 25% quantile, Q3 = 75% quantile.
However, grouping these patients according to FIGO stage
I to IV, we could show a positive correlation between tumour
stage and depression of the cytokine production in the cul-
tures after stimulation with both mitogens.
Differences between the groups and the controls were
significant for IFN-gamma (P<0.02) but not for IL-l-alpha
and IL-2 (Figure 2).
Cytokine production in WBCC ofpatients with ovarian
carcinomas
WBCC of the 47 patients with ovarian carcinomas had the
lowest cytokine levels of all tumour groups. Values of IFN-
gamma (PO0.001), IL-1-alpha (P(0.01) and IL-2 (P,<0.01)
were significantly lower than the controls.
In the cultures of the 33 patients with advanced stage
III/IV, lower IFN-gamma and IL-1-alpha values were found
than in those of 13 patients with stage I/II carcinomas after
stimulation with both mitogens (Figure 3).
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Figure 3 IFN-gamma levels in whole blood cell cultures of
patients with ovarian carcinomas and benign tumours at different
clinical stages (FIGO I-IV). mitogen: PHA 10 sgml-'.
Cytokine production in the WBCC ofthepatients with
endometrial carcinomas
In the whole blood cell cultures of this group of carcinoma
patients, significantly lower levels of IFN-gamma (P 0.001),
IL-I-alpha (P<0.01) and IL-2 (P<0.01) were also measured
than in those of the controls.
As shown in Figure 4, significantly lower IFN-gamma
levels were found in the WBCC supernatants of those 20
patients with stage III/IV carcinomas than in the cultures of
the 23 patients with stage I/II carcinomas (P<0.05). For
IL-1-alpha and IL-2 the same tendency (but no statistical
significance) was found.
Leukocyte levels in carcinomapatients and controls
In order to determine whether the observed impairment of
cytokine production was due to a depletion of lymphocytes
or monocytes, total and differential leukocyte counts were
made from all blood samples. Total leukocyte, lympocyte
and monocyte counts showed neither statistical differences
between the tumour patients and the control subjects nor
between different clinical stages of the tumour patients.
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Figure 2 IFN-gamma levels in whole blood cell cultures of
patients with cervical carcinomas at different clinical stages
(FIGO I-IV) mitogen: PHA lOIlgml-'
Contents Endometrial carcinoma
Stage I + 11 III + IV
Figure 4 IFN-gamma levels in whole blood cell cultures of
patients with endometrial carcinomas at different clinical stages
(FIGO I-IV). mitogen: PWM 51gml-'.
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Discussion
In the present study we were able to demonstrate that the
mitogen-induced production of IFN-gamma, IL-1-alpha and
IL-2 was significantly decreased in blood cell cultures from
patients with gynaecological carcinomas as compared to nor-
mal female controls. We also found that this was not due to
reduced leukocyte numbers in the blood samples. However, a
rather wide range of the cytokine values was observed not
only in the healthy control persons but also in the tumour
patients, which probably corresponds to a broad physio-
logical variation.
We found a decrease of the IFN-gamma levels with in-
creasing clinical stage or tumour burden in all four tumour
groups. This is in accordance with other papers dealing with
the immune reactivity in patients with gynaecological car-
cinomas. Both decreased lymphocyte proliferation (Wanebo
et al., 1978; Fritze & Dystant, 1984) and an impairment of
delayed type hypersensitivity (Stein et al., 1976) was found in
patients with breast cancer. Measurements of cytokine pro-
duction in cell cultures have also been used to determine the
immunological activity of breast cancer patients, but here the
results were controversial. In one study, an impaired produc-
tion of TNF was found (Zielinski et al., 1990) and a defective
expression and release of the IL-2 receptors (Hakim, 1988),
while in another study the production of IL-2 was not
diminished (Wanebo et al., 1986). In lymphocyte cultures of
patients with endometrial carcinomas a reduced IL-2 produc-
tion has been described (Yron et al., 1986).
The whole blood cell culture combined with enzymoim-
munological tests, as used in this study, in an easy to handle
and reproducible system which needs only small amounts of
blood and allows the quick testing of large numbers of blood
samples. Compared to cultures with isolated mononuclear
cells it may better reflect the in vivo situation because cell
populations are not altered and cells are not affected by the
isolation procedures. Additional cell counting in each blood
sample allows comparison of the results in the different
tumour groups and controls. This could be supplemented
with a T-cell subset phenyotyping. However, when compar-
ing subsets in samples of other patients with solid carcinomas
and controls no significant differences were seen (Elsasser-
Beile et al., 1992; 1993), so we doubt if phenotyping would
give much more information.
As already shown in another study (Elsasser-Beile et al.,
1992), of the tested cytokines IFN-gamma seems to be the
best parameter for evaluating the cellular immunological
competence of a patient because it is produced only by
T-cells and NK-cells in high amounts upon T-cell activation
and does not bind to its receptor as does IL-2. Since the
whole blood system contains only less than 10% monocytes,
the monokine secretion is relatively low and concentration
differences are more difficult to demonstrate. This might
explain that significant differences between patient groups
with different tumour stages were seen with IFN-gamma
only. From kinetic experiments, an incubation time of four
days was chosen which is optimal for IFN-gamma and IL-1-
alpha and acceptable for IL-2. For TNF-alpha, shorter
incubation times might be better.
To our knowledge the present study is the first to provide
information on the production of cytokines by peripheral
lymphocytes from a rather 'large group of patients with
various gynaecological carcinomas of different clinical stages,
where a decreased cytokine production closely associated
with the advancement ofthe tumour stage could be shown in
all groups of carcinomas.
A broad variation was seen in patients with breast cancer
and cervical carcinomas, where those patients with small
localised tumours had only slightly lower lymphokine values
than the controls, whereas those with metastasising tumours
had much lower values. The situation was different in
patients with ovarian and endometrial carcinomas. These
carcinomas are mostly diagnosed in an advanced stage and
also primary tumours comprise larger volumes.
From our results, we suggest that malignant disease
gradually leads to a depression of the cellular immunity
potential in the host as reflected by a lower cytokine produc-
tion of his/her immunocompetent cells. A possible explana-
tion for this impaired function of the lymphocytes and
monocytes could be the presence of circulating immunosup-
pressive factors or an induction of suppressor cell popula-
tions as already postulated by other authors (Zembala et al.,
1977; Bjercke et al., 1986).
Our studies may help to clarify the state of the tumour-
host relationship and they might be suitable for finding out
those patients who are the most immunosuppressed and
therefore may have a poor prognosis.
It will be interesting to determine whether the restoration
of a decreased cytokine production would be indicative for a
clinical amelioration and thus to verify, whether our system
will provide a means to give an indication of the course of
the cancerous disease.
The authors wish to thank D. Gierschner, B. Hofflin, F. Jehle and R.
Schuihle for their excellent technical assistance.
PHA, phytohaemagglutinin; PWM, pokeweed mitogens; ELISA,
enzyme linked immunoassay; IL, interleukin; IFN, interferon; TNF,
tumour necrosis factor; mab, monoclonal antibody; pod, peroxidase.
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